Drug factory · FDA FEI 3014008486
Renata PLC (general Plant-2)
Rajendrapur General Facility, Noyapara, Bhawal, Mirzapur, Rajendrapur, Gazipur, Bangladesh
Problems found, fixed voluntarily at FDA's last inspection, Jan 30, 2020.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
1 drug inspection on record since 2020: 0 with no problems, 1 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Cabergoline | Makes it, tests it, packages it and labels it | Cranbury Pharmaceuticals, LLC | 27808-315 |
| Metoprolol | Makes it, tests it, packages it and labels it | Renata Limited (General Plant-2) | 82727-001, 82727-002 |
| Risperidone | Makes it | Westminster Pharmaceuticals, LLC | 69367-368, 69367-369, 69367-370 +3 |
| Rosuvastatin | Makes it, tests it, packages it and labels it | Westminster Pharmaceuticals, LLC | 69367-359, 69367-360, 69367-361 +1 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Jan 30, 2020 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
Registered with FDA for: analysis; label; manufacture; pack.